Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

Buzz on the Bullboards: Markets underperforming, or is the best yet to come?

So, the “September rally” didn’t really pan out as many indices hit lows not seen in months, but at least interest rates were kept firm for now, so that is some good news, right? Investors have been worried about the possibility o...
Jonathon Brown | September 28, 2023 |

Review of Massively Successful Tech Puts Trades, and Why the Market Has Probably Hit a Bottom Here

Technical analyst Clive Maund discusses trading activity that took advantage of the market's drop. This article was conceived as a "souvenir article" to assist subscribers who did the trade—and I know from feedback that a significant number of you did—in glo...
Streetwise Reports | March 2, 2020 |

January 2020 in Review: Barometric Bedlam

Back in the 1980s, I had a boss that was right out of Monty Python. A Canadian by birth, he was the son of a very wealthy English nobleman who spent a number of years in Brazil as CEO of Brazilian Traction, where he was raised by servants and nannies and attended private ...
Streetwise Reports | February 4, 2020 |

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

An explanation of the categorization and its implications are provided in a Paradigm Capital report. In a May 30 research note, Paradigm Capital analyst Rahul Sarugaser reported that Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) lead product candidate ZW25 wa...
Streetwise Reports | June 10, 2019 |

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. Biopharmaceutical company Cerecor Inc. (CERC:NASDAQ) , which focuses on development and ...
Streetwise Reports | October 16, 2019 |

Buzz on the Bullboards: Debates among the top sectors

If you’re looking to see the stocks that investors have been keeping an eye on over the past week, you’ve come to the right place. The Bullboard community regularly acts as a microcosm of investor sentiment at large. Great results lead to a...
Jonathon Brown | August 18, 2022 |

Coverage Initiated on Company at 'Forefront of the Telehealth Revolution'

A review of CloudMD Software & Services and the reasons why it makes a compelling investment are provided in a Beacon Securities report. In a June 4 research note, analyst Gabriel Leung reported that Beacon Securities initiated coverage on CloudMD Software & Servi...
Streetwise Reports | June 9, 2020 |

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. In a March 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Nabriva Therapeutics Plc (NBRV:NASDAQ) has two antibiotics up for approval...
Streetwise Reports | March 21, 2019 |
1 2 3 4 5 6 7 8 9 10 ...